Stephens Issues Pessimistic Forecast for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT) had its price target trimmed by Stephens from $7.00 to $5.00 in a research note released on Thursday morning,Benzinga reports. The firm currently has an equal weight rating on the stock.

Several other research analysts also recently issued reports on the stock. Wells Fargo & Company lowered their price target on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a report on Tuesday, January 21st. Citigroup lowered their price target on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a report on Friday, January 10th. Piper Sandler reduced their price objective on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 11th. Canaccord Genuity Group reduced their price objective on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 21st. Finally, Stifel Nicolaus reduced their price objective on shares of Health Catalyst from $10.00 to $5.00 and set a “hold” rating on the stock in a research note on Thursday, February 27th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Health Catalyst has a consensus rating of “Moderate Buy” and a consensus target price of $9.27.

Health Catalyst Stock Down 3.2 %

Shares of NASDAQ:HCAT opened at $4.29 on Thursday. The company has a fifty day moving average of $5.73 and a 200-day moving average of $7.16. The company has a market capitalization of $301.21 million, a PE ratio of -3.18 and a beta of 1.41. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst has a 52-week low of $3.76 and a 52-week high of $9.24.

Insider Buying and Selling at Health Catalyst

In other Health Catalyst news, insider Linda Llewelyn sold 6,442 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $7.88, for a total transaction of $50,762.96. Following the sale, the insider now owns 98,702 shares of the company’s stock, valued at approximately $777,771.76. This represents a 6.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $7.51, for a total transaction of $39,119.59. Following the sale, the chief operating officer now directly owns 91,253 shares in the company, valued at $685,310.03. This trade represents a 5.40 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 41,243 shares of company stock valued at $273,620. 2.50% of the stock is currently owned by insiders.

Institutional Trading of Health Catalyst

A number of institutional investors have recently bought and sold shares of the company. Probity Advisors Inc. raised its holdings in shares of Health Catalyst by 33.2% during the fourth quarter. Probity Advisors Inc. now owns 30,692 shares of the company’s stock valued at $217,000 after purchasing an additional 7,647 shares during the period. Mackenzie Financial Corp acquired a new position in shares of Health Catalyst during the fourth quarter valued at about $248,000. PharVision Advisers LLC acquired a new position in shares of Health Catalyst during the fourth quarter valued at about $185,000. Two Sigma Advisers LP raised its holdings in shares of Health Catalyst by 72.7% during the fourth quarter. Two Sigma Advisers LP now owns 29,700 shares of the company’s stock valued at $210,000 after purchasing an additional 12,500 shares during the period. Finally, Two Sigma Investments LP acquired a new position in shares of Health Catalyst during the fourth quarter valued at about $496,000. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.